

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and  
Waiver under 18 U.S.C. § 208(b)(3)

Ruth M. Parker, M.D.

**Committees:** Joint Nonprescription Drugs Advisory Committee and Endocrinologic  
and Metabolic Drugs Advisory Committee Meeting

**Meeting Date:** January 23, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to new drug application (NDA) 21-887, proposing over-the-counter (OTC) use of Orlistat (tetrahydrolipstatin) 60 milligram (mg) capsules, sponsored by GlaxoSmithKline Consumer Healthcare, L.P., an associate of GlaxoSmithKline PLC, to promote weight loss in overweight adults when used along with a reduced calorie and low fat diet, I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Co-editor of an unrelated journal supplement that is supported by an unrestricted educational grant.	Competitor	Less than \$5,001 a year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

\_\_\_\_\_  
Signature of SGE

1/2/06

\_\_\_\_\_  
Date